Zura Bio (ZURA) had its price target raised by Chardan Capital from $10.00 to $11.00. They now have a "buy" rating on the stock.
Zura Bio (ZURA) had its price target lowered by Oppenheimer Holdings, Inc. from $16.00 to $15.00. They now have an "outperform" rating on the stock.
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
Zura Bio to Participate in Upcoming Investor Conferences